TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23727002

Group type: EXPERIMENTAL
Intervention: HBsAg-1018 (2 doses at 0 and 4 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: HBsAg-Eng (3 doses at 0, 4, and 24 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HBsAg-1018
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HBsAg-1018 and HBsAg-Eng
Number of subjects: 0
Study: 21732272

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 34
Study: 19390535

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 2720

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 2720
Study: 16495471

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 microg daily)
Number of subjects: 1004
Study: 12938843

Group type: EXPERIMENTAL
Intervention: Mandibular advancement splint (MAS)
Number of subjects: 100
Study: 12825772

Group type: EXPERIMENTAL
Intervention: Animacy decision task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Odd-digit identification task
Number of subjects: 0
Study: 9576383

Group type: EXPERIMENTAL
Intervention: DTaP plus oral polio vaccine (OPV)
Number of subjects: 711

Group type: EXPERIMENTAL
Intervention: DTaP plus eIPV (separate injections)
Number of subjects: 711

Group type: EXPERIMENTAL
Intervention: DTaP-eIPV combined as a single injection
Number of subjects: 711

Group type: EXPERIMENTAL
Intervention: DTaP-eIPV combined, plus a separate injection of PRP-T
Number of subjects: 711

Group type: EXPERIMENTAL
Intervention: DTaP-eIPV combined and reconstituting PRP-T, as a single injection
Number of subjects: 711

Group type: EXPERIMENTAL
Intervention: Booster dose of DTaP reconstituting PRP-T as a single injection
Number of subjects: 711

Group type: EXPERIMENTAL
Intervention: Concomitant PRP-T with DTaP-eIPV
Number of subjects: 711

Group type: EXPERIMENTAL
Intervention: All groups after eIPV
Number of subjects: 711

Group type: EXPERIMENTAL
Intervention: Groups 4 and 5 after eIPV
Number of subjects: 711
Study: 8550249

Group type: EXPERIMENTAL
Intervention: Sickle Cell Trait (SCT) carriers
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 13
Study: 1978163

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms inhaled before allergen challenge
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 744812

Group type: EXPERIMENTAL
Intervention: Blood pressure measurement during cardiovascular screening examination
Number of subjects: 8397

Group type: EXPERIMENTAL
Intervention: Standardised training techniques for observers
Number of subjects: 8397

Group type: EXPERIMENTAL
Intervention: Environmental factors (time of day and room temperature)
Number of subjects: 8397

Group type: EXPERIMENTAL
Intervention: Age and overweight
Number of subjects: 8397
Study: 31856741

Group type: EXPERIMENTAL
Intervention: Impaired kidney function (eGFR < 60 ml/min/1.73m²)
Number of subjects: 2931

Group type: EXPERIMENTAL
Intervention: Mildly impaired kidney function (eGFR 45-<60 ml/min/1.73m²)
Number of subjects: 2931

Group type: COMPARATOR
Intervention: No association found
Number of subjects: 2931
Study: 28535809

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (0.045 mg/kg/dose) twice daily for 4 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 25979561

Group type: COMPARATOR
Intervention: 500 cc Saline by rectal enema
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: six bisacodyl tablets
Number of subjects: 79
Study: 23490325

Group type: EXPERIMENTAL
Intervention: Epimacular brachytherapy (EMBT) with 2 mandated monthly ranibizumab injections followed by pro re nata (PRN) ranibizumab
Number of subjects: 494

Group type: COMPARATOR
Intervention: 3 mandated monthly ranibizumab injections followed by mandated quarterly plus PRN ranibizumab
Number of subjects: 494
Study: 21806770

Group type: EXPERIMENTAL
Intervention: Home and clinic BP monitoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 19333160

Group type: EXPERIMENTAL
Intervention: Oral glucose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Facilitated tucking by parents (FTP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Opioid (oxycodone)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (oral water)
Number of subjects: 20
Study: 16937963

Group type: EXPERIMENTAL
Intervention: Ribose (625 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 15309425

Group type: EXPERIMENTAL
Intervention: Soymilk containing isoflavones (soy+)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Transdermal progesterone (TPD+)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Combination of soy+ and TPD+
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo (isoflavone-poor soymilk and progesterone-free cream)
Number of subjects: 89
Study: 11412253

Group type: EXPERIMENTAL
Intervention: Minilaparotomy
Number of subjects: 84

Group type: COMPARATOR
Intervention: Conventional laparotomy
Number of subjects: 84
Study: 9441144

Group type: EXPERIMENTAL
Intervention: 1 day catheterization
Number of subjects: 50

Group type: COMPARATOR
Intervention: 3 days catheterization
Number of subjects: 50
Study: 8221844

Group type: EXPERIMENTAL
Intervention: Brachial approach with 5 French preformed Judkins catheters
Number of subjects: 100

Group type: COMPARATOR
Intervention: Femoral approach with 6 French catheters
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 100
Study: 31960907

Group type: EXPERIMENTAL
Intervention: ICSI (Intracytoplasmic Sperm Injection)
Number of subjects: 536

Group type: COMPARATOR
Intervention: Mild or severe MFI
Number of subjects: 536

Group type: COMPARATOR
Intervention: Surgical sperm extraction
Number of subjects: 536
Study: 30262332

Group type: EXPERIMENTAL
Intervention: Eluvia stent
Number of subjects: 465

Group type: COMPARATOR
Intervention: Zilver PTX stent
Number of subjects: 465
Study: 27942041

Group type: EXPERIMENTAL
Intervention: Counterfactual thinking
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Prefactual thinking
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (unrelated filler task)
Number of subjects: 84
Study: 25636288

Group type: EXPERIMENTAL
Intervention: Rod type mandibular advancement device (MAD)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Controllable type mandibular advancement device (MAD)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both types of MADs
Number of subjects: 22

Group type: COMPARATOR
Intervention: Rod type MAD vs Controllable type MAD
Number of subjects: 22
Study: 22480835

Group type: EXPERIMENTAL
Intervention: Laparoscopic pyloromyotomy (LP)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Open pyloromyotomy (OP)
Number of subjects: 74
Study: 20199137

Group type: EXPERIMENTAL
Intervention: Liraglutide (0.9 mg once daily)
Number of subjects: 411

Group type: COMPARATOR
Intervention: Glibenclamide (2.5 mg/day, once or twice daily)
Number of subjects: 411
Study: 18666504

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conventional diamond bur
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Clearfil S3 Bond
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: OptiBond FL
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Adper Prompt L-Pop
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 35
Study: 15639169

Group type: EXPERIMENTAL
Intervention: 21-mg transdermal nicotine patch (smokers)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 7-mg transdermal nicotine patch (nonsmokers)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo (nonsmokers)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo (smokers)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Not applicable (RVIP task)
Number of subjects: 47
Study: 12860725

Group type: EXPERIMENTAL
Intervention: Chemokine antagonist
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 9884375

Group type: EXPERIMENTAL
Intervention: Ultrasound thrombolysis (CUT) at 41 kHz, 18 W, for ≤6 minutes
Number of subjects: 20
Study: 9275690

Group type: EXPERIMENTAL
Intervention: Selenium supplementation
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Selenium levels in tumor tissue
Number of subjects: 44
Study: 1997083

Group type: EXPERIMENTAL
Intervention: Bupivacaine (40 ml of 0.25%)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Saline (40 ml)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Bupivacaine and Saline
Number of subjects: 72
Study: 6392105

Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir (30 mg/kg per day for five days)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 31122212

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus prednisone (AAP) and Androgen Deprivation Therapy (ADT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Apalutamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of AAP (without ADT) and apalutamide
Number of subjects: 0
Study: 29789507

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (CAF) consumption (5.5 mg/kg of caffeine)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Decaffeinated coffee (DEC) consumption
Number of subjects: 12
Study: 27426245

Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 795

Group type: COMPARATOR
Intervention: Erlotinib
Number of subjects: 795
Study: 24981585

Group type: COMPARATOR
Intervention: Endovenous steam ablation (EVSA) high dose
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Endovenous steam ablation (EVSA)
Number of subjects: 227
Study: 23108493

Group type: EXPERIMENTAL
Intervention: Weight maintenance among healthy weight employees
Number of subjects: 1228

Group type: EXPERIMENTAL
Intervention: Weight gain among obese employees
Number of subjects: 1228

Group type: EXPERIMENTAL
Intervention: Weight loss among healthy weight employees
Number of subjects: 1228

Group type: EXPERIMENTAL
Intervention: Male participants, not depressed, nonsmokers, and lower baseline absenteeism
Number of subjects: 1228
Study: 19237660

Group type: EXPERIMENTAL
Intervention: Salsalate (4500 mg/d)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 17975183

Group type: EXPERIMENTAL
Intervention: mature-PR3-ANCA levels
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: pro-PR3-ANCA levels
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: PR3-ANCA levels increase
Number of subjects: 156
Study: 15165408

Group type: EXPERIMENTAL
Intervention: Verum LM remedy
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 12234030

Group type: EXPERIMENTAL
Intervention: Direct anterior electron field treatment
Number of subjects: 266

Group type: COMPARATOR
Intervention: Tangential photon treatment
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Adjuvant systemic therapy
Number of subjects: 266
Study: 9620901

Group type: EXPERIMENTAL
Intervention: Intranasal cold dry air (CDA)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Histamine
Number of subjects: 23
Study: 7988978

Group type: EXPERIMENTAL
Intervention: Cefotaxime i.v. followed by Cefixime oral (2 x 2 g cefotaxime i.v. for 7 to 10 days, then 1 x 400 mg cefixime for 5 to 8 days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cefotaxime parenteral (2 x 2 g cefotaxime for 48 to 72 hours)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cefotaxime i.v. followed by Cefixime oral
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cefotaxime parenteral
Number of subjects: 100
Study: 2590626

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS) administered twice daily (Group A)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS) administered four times a day (Group B)
Number of subjects: 112
Study: 1090979

Group type: EXPERIMENTAL
Intervention: Glucagon
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 31474116

Group type: EXPERIMENTAL
Intervention: Sodium-glucose cotransporter-2 inhibitor dapagliflozin
Number of subjects: 16790

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 16790
Study: 28343676

Group type: EXPERIMENTAL
Intervention: Titanium abutments
Number of subjects: 12

Group type: COMPARATOR
Intervention: Zirconia abutments
Number of subjects: 12
Study: 25764916

Group type: EXPERIMENTAL
Intervention: Pre-procedure spinal ultrasound (US) to determine the optimal lumbar level for injection
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group determined the level of injection by palpation
Number of subjects: 80
Study: 24147175

Group type: EXPERIMENTAL
Intervention: Praziquantel treatment during pregnancy
Number of subjects: 1343

Group type: COMPARATOR
Intervention: Control (placebo treatment during pregnancy)
Number of subjects: 1343
Study: 21868338

Group type: EXPERIMENTAL
Intervention: TKA with patellar resurfacing
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group (TKA without patellar resurfacing)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Patients with varus or valgus knee
Number of subjects: 128
Study: 19422464

Group type: EXPERIMENTAL
Intervention: Glucose levels in the second quartile (5.3-5.7 mmol L(‐1))
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Glucose levels in the third quartile (5.7-6.6 mmol L(‐1))
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Glucose levels in the fourth quartile (>= 6.6 mmol L(‐1))
Number of subjects: 188
Study: 17461847

Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation (B-complex, C and E)
Number of subjects: 1078
Study: 15026833

Group type: EXPERIMENTAL
Intervention: Near-term suicidal patients
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Major depressed patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-depressed controls
Number of subjects: 30
Study: 11230853

Group type: EXPERIMENTAL
Intervention: WBC count > 10,000
Number of subjects: 7651

Group type: COMPARATOR
Intervention: WBC count < 10,000
Number of subjects: 7651
Study: 9551672

Group type: EXPERIMENTAL
Intervention: Phlebotomy (500-ml every 2 weeks until iron deficiency achieved) followed by 6-month course of alpha-interferon 2b (3 mu tiw)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (21 patients monitored for 6-8 weeks without phlebotomy)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Phlebotomy followed by interferon therapy
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study: 7817727

Group type: EXPERIMENTAL
Intervention: Expectant mothers aged ≥ 40 years
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Smokers with placental abruption
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Women with medical treatment for essential hypertension
Number of subjects: 205

Group type: COMPARATOR
Intervention: Post dated pregnancies estimated from first day of last menstrual period
Number of subjects: 205

Group type: COMPARATOR
Intervention: Short symphysis-fundal height
Number of subjects: 205

Group type: COMPARATOR
Intervention: Fetal birthweight in case pregnancies
Number of subjects: 205
Study: 2646847

Group type: EXPERIMENTAL
Intervention: Lignocaine (1%) mixed with propofol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Glucose (5%)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg/kg)
Number of subjects: 40
Study: 9953

Group type: EXPERIMENTAL
Intervention: Intramuscular pethidine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intramuscular diamorphine
Number of subjects: 8
Study: 30240335

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Motor imagery
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: tDCS (combined with motor imagery)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 4

Group type: COMPARATOR
Intervention: Cathodal tDCS
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control group (without stimulation)
Number of subjects: 4
Study: 29465583

Group type: EXPERIMENTAL
Intervention: Living High-Training Low (LHTL)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Living Low-Training Low (LLTL)
Number of subjects: 35
Study: 26828788

Group type: EXPERIMENTAL
Intervention: docetaxel plus bevacizumab
Number of subjects: 100

Group type: COMPARATOR
Intervention: docetaxel
Number of subjects: 100
Study: 24141905

Group type: EXPERIMENTAL
Intervention: Oxidized zirconium total knee prosthesis
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cobalt-chromium total knee prosthesis
Number of subjects: 12
Study: 22334314

Group type: EXPERIMENTAL
Intervention: Final Kissing Balloon Dilatation (FKBD)
Number of subjects: 75

Group type: COMPARATOR
Intervention: No FKBD
Number of subjects: 75
Study: 21199410

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 added to systemic steroid treatment for 2 weeks.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Systemic steroid treatment for 2 weeks (control group).
Number of subjects: 120
Study: 17469983

Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 16014882

Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg daily)
Number of subjects: 731

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 731
Study: 12201869

Group type: EXPERIMENTAL
Intervention: INF-alpha 10 MU/m2 and LAM 4 mg/kg (max 100 mg) for 6 months, then LAM alone for 6 months
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: LAM alone for the first 2 months, then INF-alpha added for 6 months, then LAM alone for 4 months
Number of subjects: 32

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 32
Study: 10885834

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) ET-1 concentration in patients with HIV encephalopathy (grade 1-3)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Cerebrospinal fluid (CSF) ET-1 concentration in patients without encephalopathy (grade 0-0.5)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Correlation between ET-1 CSF concentrations and degree of HIV encephalopathy
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Correlation between ET-1 levels in CSF and IgG serum to CSF ratio
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Correlation between HIV encephalopathy and CSF total protein, IgG, albumin, or serum to CSF ratio of IgG or albumin
Number of subjects: 48
Study: 8943865

Group type: EXPERIMENTAL
Intervention: CD2 antigen positive leukemic cells (> 75% positivity)
Number of subjects: 651

Group type: EXPERIMENTAL
Intervention: CD2‐negative patients
Number of subjects: 651

Group type: EXPERIMENTAL
Intervention: Standard risk T‐lineage ALL (CD2‐negative)
Number of subjects: 651

Group type: COMPARATOR
Intervention: High-risk T‐lineage ALL (CD2 positive)
Number of subjects: 651
Study: 2248073

Group type: EXPERIMENTAL
Intervention: Moclobemide (300 mg daily for the first 5 days, then up to 600 mg)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Imipramine (starting at 33 mg, increased to 100 mg/day in the first 5 days, then could be further increased)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 7227770

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Mylanta II
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cimetidine (in smokers)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Mylanta II (in smokers)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cimetidine (in nonsmokers)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Mylanta II (in nonsmokers)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Smoking (effect on healing)
Number of subjects: 50
Study: 30280328

Group type: EXPERIMENTAL
Intervention: New complete denture and simple dietary advice
Number of subjects: 0

Group type: COMPARATOR
Intervention: New complete denture and denture care advice
Number of subjects: 0
Study: 27744075

Group type: EXPERIMENTAL
Intervention: Ringer acetate (RAC)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES; 130 kDa/0.4)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 58

Group type: COMPARATOR
Intervention: Prone position
Number of subjects: 58
Study: 26411328

Group type: EXPERIMENTAL
Intervention: Mitiglinide (10 mg tid) with insulin glargine
Number of subjects: 156

Group type: COMPARATOR
Intervention: Voglibose (0.2 mg tid) with insulin glargine
Number of subjects: 156
Study: 24684973

Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Number of subjects: 489
Study: 23181446

Group type: EXPERIMENTAL
Intervention: Global secondary low back pain prevention program (two-hour information session + five weekly 90-min exercise sessions)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 100
Study: 19819448

Group type: EXPERIMENTAL
Intervention: Dienogest 2mg/day
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Dienogest 4mg/day
Number of subjects: 64

Group type: COMPARATOR
Intervention: Dienogest 1mg/day
Number of subjects: 64
Study: 17352961

Group type: EXPERIMENTAL
Intervention: Probiotic bacteria (1 x 10^10 colony-forming units/d)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Methylcellulose (placebo)
Number of subjects: 50
Study: 15860519

Group type: EXPERIMENTAL
Intervention: Coronary stent implantation
Number of subjects: 142

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 142
Study: 11994812

Group type: EXPERIMENTAL
Intervention: Home exercise program focusing on strengthening hip and knee extensors
Number of subjects: 23

Group type: COMPARATOR
Intervention: Lifestyle modification techniques to avoid shoulder overuse
Number of subjects: 23

Group type: COMPARATOR
Intervention: Combination of exercise and lifestyle modification
Number of subjects: 23
Study: 9816650

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 60 micrograms PGE1 over a period of 2 hours
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 20
Study: 7694917

Group type: EXPERIMENTAL
Intervention: Virtual reality graded exposure treatment (N = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Waiting-list comparison group (N = 7)
Number of subjects: 20
Study: 2695647

Group type: EXPERIMENTAL
Intervention: Nipple Stimulation Contraction Stress Tests (BSTs)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Oxytocin Challenge Tests (OCTs)
Number of subjects: 103